<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395925</url>
  </required_header>
  <id_info>
    <org_study_id>CEL THYRO01</org_study_id>
    <nct_id>NCT03395925</nct_id>
  </id_info>
  <brief_title>Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid</brief_title>
  <official_title>Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympus Surgical Technologies Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olympus Surgical Technologies Europe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid nodules are among the common alterations of the thyroid. Depending on the detection&#xD;
      method the prevalence is between 20% and 50%, whereas the incidence increases with&#xD;
      improvement of ultrasonic technology. The CelonPro Surge bipolar coagulation electrode&#xD;
      operated with the compatible power control unit and compatible tube pump is indicated for&#xD;
      ablation and coagulation of soft tissue, including thermal inactivation and/or volume&#xD;
      reduction of locally defined tissue areas, such as tumors and metastases.&#xD;
&#xD;
      The primary objective of the study is to assess the influence of radiofrequency ablation due&#xD;
      to thyroid volume after 24 hours, 3 months, 6 months and 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to demonstrate reduction of thyroid volume following radiofrequency ablation of thyroid tissue</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint is the reduction of thyroid volume at 12-Month follow-up visit. A responder to the radiofrequency treatment is defined as a subject with any reduction of the thyroid volume.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid Nodule</condition>
  <arm_group>
    <arm_group_label>Celon Pro Surge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of thyroid tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celon Pro Surge</intervention_name>
    <description>bipolar coagulation electrode intended for tissue heating</description>
    <arm_group_label>Celon Pro Surge</arm_group_label>
    <other_name>Bipolar coagulation electrode, tissue heating and ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given written (personally signed and dated) informed consent&#xD;
             before completing any study-related procedures (i.e. any assessment or evaluation that&#xD;
             would not have formed part of their normal medical care).&#xD;
&#xD;
          -  The patient must be aged 18yrs or older.&#xD;
&#xD;
          -  The patient must be able to understand, and be willing to comply with the requirements&#xD;
             of the protocol&#xD;
&#xD;
          -  The patient is not pregnant&#xD;
&#xD;
          -  The patient has the diagnosis of benign thyroid nodules, struma diffusa, struma&#xD;
             uninodosa, struma multinodosa, struma per magna, Thyroidea nodosa or Thyroidea&#xD;
             multinodosa&#xD;
&#xD;
          -  The patient rejected surgery The patient rejected sole radioiodine therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malign nodules&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pacemaker near the target issue (&lt;4cm)&#xD;
&#xD;
          -  Nerve stimulating device&#xD;
&#xD;
          -  High fever&#xD;
&#xD;
          -  Prosthesis for the inner ear&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HÃ¼dayi Korkusuz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johann-Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid Nodule</keyword>
  <keyword>Bipolar coagulation electrode</keyword>
  <keyword>radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Nodule</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

